Search Results - "Heaney, Mark L"

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era by Goyal, Gaurav, Heaney, Mark L., Collin, Matthew, Cohen-Aubart, Fleur, Vaglio, Augusto, Durham, Benjamin H., Hershkovitz-Rokah, Oshrat, Girschikofsky, Michael, Jacobsen, Eric D., Toyama, Kazuhiro, Goodman, Aaron M., Hendrie, Paul, Cao, Xin-xin, Estrada-Veras, Juvianee I., Shpilberg, Ofer, Abdo, André, Kurokawa, Mineo, Dagna, Lorenzo, McClain, Kenneth L., Mazor, Roei D., Picarsic, Jennifer, Janku, Filip, Go, Ronald S., Haroche, Julien, Diamond, Eli L.

“…Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK…”
Get full text

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease by Diamond, Eli L., Dagna, Lorenzo, Hyman, David M., Cavalli, Giulio, Janku, Filip, Estrada-Veras, Juvianee, Ferrarini, Marina, Abdel-Wahab, Omar, Heaney, Mark L., Scheel, Paul J., Feeley, Nancy K., Ferrero, Elisabetta, McClain, Kenneth L., Vaglio, Augusto, Colby, Thomas, Arnaud, Laurent, Haroche, Julien

“…Erdheim-Chester disease (ECD) is a rare, non-Langerhans histiocytosis. Recent findings suggest that ECD is a clonal disorder, marked by recurrent BRAFV600E…”
Get full text

Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs by HEANEY, Mark L, GARDNER, Jeffrey R, KARASAVVAS, Nicos, GOLDE, David W, SCHEINBERG, David A, SMITH, Emily A, O'CONNOR, Owen A

“…Vitamin C is an antioxidant vitamin that has been hypothesized to antagonize the effects of reactive oxygen species-generating antineoplastic drugs. The…”
Get full text

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia by Leeksma, Alexander C., Taylor, Justin, Wu, Bian, Gardner, Jeffrey R., He, Jie, Nahas, Michelle, Gonen, Mithat, Alemayehu, Wendimagegn G., te Raa, Doreen, Walther, Tatjana, Hüllein, Jennifer, Dietrich, Sascha, Claus, Rainer, de Boer, Fransien, de Heer, Koen, Dubois, Julie, Dampmann, Maria, Dürig, Jan, van Oers, Marinus H. J., Geisler, Christian H., Eldering, Eric, Levine, Ross L., Miller, Vincent, Mughal, Tariq, Lamanna, Nicole, Frattini, Mark G., Heaney, Mark L., Zelenetz, Andrew, Zenz, Thorsten, Abdel-Wahab, Omar, Kater, Arnon P.

“…Genomic analyses of chronic lymphocytic leukemia (CLL) identified somatic mutations and associations of clonal diversity with adverse outcomes. Clonal…”
Get full text

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies by O'CONNOR, Owen A, HEANEY, Mark L, ZELENETZ, Andrew D, FRANKEL, Stanley, RICHON, Victoria, MARKS, Paul, KELLY, William K, SCHWARTZ, Lawrence, RICHARDSON, Stacie, WILLIM, Robert, MACGREGOR-CORTELLI, Barbara, CURLY, Tracey, MOSKOWITZ, Craig, PORTLOCK, Carol, HORWITZ, Steven

“…To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic…”
Get full text

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms by Hobbs, Gabriela S, Hanasoge Somasundara, Amritha Varshini, Kleppe, Maria, Litvin, Rivka, Arcila, Maria, Ahn, Jihae, McKenney, Anna Sophia, Knapp, Kristina, Ptashkin, Ryan, Weinstein, Howard, Heinemann, Murk-Hein, Francis, Jasmine, Chanel, Suzanne, Berman, Ellin, Mauro, Michael, Tallman, Martin S, Heaney, Mark L, Levine, Ross L, Rampal, Raajit K

Get full text

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera by Tremblay, Douglas, Srisuwananukorn, Andrew, Ronner, Lukas, Podoltsev, Nikolai, Gotlib, Jason, Heaney, Mark L., Kuykendall, Andrew, O'Connell, Casey L., Shammo, Jamile M., Fleischman, Angela, Mesa, Ruben, Yacoub, Abdulraheem, Hoffman, Ronald, Moshier, Erin, Zubizarreta, Nicole, Mascarenhas, John

Get full text

Inhibition of Human Peptide Deformylase Disrupts Mitochondrial Function by Escobar-Alvarez, Sindy, Gardner, Jeffrey, Sheth, Aneesh, Manfredi, Giovanni, Yang, Guangli, Ouerfelli, Ouathek, Heaney, Mark L., Scheinberg, David A.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses by LAMANNA, Nicole, JURCIC, Joseph G, ZELENETZ, Andrew D, WEISS, Mark A, NOY, Ariela, MASLAK, Peter, GENCARELLI, Alison N, PANAGEAS, Katherine S, HEANEY, Mark L, BRENTJENS, Renier J, GOLDE, David W, SCHEINBERG, David A

“…Modern combination strategies are active in chronic lymphocytic leukemia (CLL) but can have significant myelosuppression and immunosuppression that may require…”
Get full text

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial by Gotlib, Jason, Reiter, Andreas, Radia, Deepti H., Deininger, Michael W., George, Tracy I., Panse, Jens, Vannucchi, Alessandro M., Platzbecker, Uwe, Alvarez-Twose, Iván, Mital, Andrzej, Hermine, Olivier, Dybedal, Ingunn, Hexner, Elizabeth O., Hicks, Lisa K., Span, Lambert, Mesa, Ruben, Bose, Prithviraj, Pettit, Kristen M., Heaney, Mark L., Oh, Stephen T., Sen, Jayita, Lin, Hui-Min, Mar, Brenton G., DeAngelo, Daniel J.

“…Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-driven hematologic neoplasm characterized by mast cell infiltration and shortened survival. We…”
Get full text

Glasdegib in newly diagnosed acute myeloid leukemia by Sarkaria, Shawn M, Heaney, Mark L

“…Acute myeloid leukemia (AML) is an aggressive blood cancer that proves fatal for the majority of affected individuals. Older patients are particularly…”
Get full text

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis by Ronner, Lukas, Podoltsev, Nikolai, Gotlib, Jason, Heaney, Mark L., Kuykendall, Andrew T., O'Connell, Casey, Shammo, Jamile, Fleischman, Angela G., Scherber, Robyn M., Mesa, Ruben, Yacoub, Abdulraheem, Perkins, Cecelia, Meckstroth, Shelby, Behlman, Lindsey, Chiaramonte, Matthew, Salehi, Mahta, Ziadkhanpour, Kimia, Nguyen, Hellen, Siwoski, Olivia, Hung, Annie Kwok, Janania Martinez, Michelle, Nguyen, Jenny, Patel, Sagar, Kollipara, Revathi, Dave, Ami, Randall, Megan, Grant, Michael, Harrison, Mitchell, Fernandez Soto, Paola, Tremblay, Douglas, Hoffman, Ronald, Moshier, Erin, Mascarenhas, John

“…There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera…”
Get full text

Soluble receptors in human disease by Heaney, Mark L., Golde, David W.

“…Soluble cytokine receptors naturally arise from genes encoding membrane‐bound receptors or are direct derivatives of the receptors themselves. There is…”
Get full text

Can the treatment of myeloproliferative neoplasms be both good and bad for you? by Heaney, Mark L

Get full text

Saving orphans: BRAF targeting of histiocytosis by Heaney, Mark L.

“…In this issue of Blood, Haroche and colleagues report significant therapeutic activity of the BRAF inhibitor, vemurafenib, in 3 patients with rare histiocytic…”
Get full text

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia by ROSENBLAT, Todd L, MCDEVITT, Michael R, LARSON, Steven M, SCHEINBERG, David A, JURCIC, Joseph G, MULFORD, Deborah A, PANDIT-TASKAR, Neeta, DIVGI, Chaitanya R, PANAGEAS, Katherine S, HEANEY, Mark L, CHANEL, Suzanne, MORGENSTERN, Alfred, SGOUROS, George

“…Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute myeloid leukemia (AML)…”
Get full text

A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia by Mallikaratchy, Prabodhika R, Ruggiero, Alessandro, Gardner, Jeffrey R, Kuryavyi, Vitaly, Maguire, William F, Heaney, Mark L, McDevitt, Michael R, Patel, Dinshaw J, Scheinberg, David A

“…Long-term survival still eludes most patients with leukemia and non-Hodgkin's lymphoma. No approved therapies target the hallmark of the B cell, its mIgM, also…”
Get full text

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial by Oh, Stephen T., Talpaz, Moshe, Gerds, Aaron T., Gupta, Vikas, Verstovsek, Srdan, Mesa, Ruben, Miller, Carole B., Rivera, Candido E., Fleischman, Angela G., Goel, Swati, Heaney, Mark L., O'Connell, Casey, Arcasoy, Murat O., Zhang, Yafeng, Kawashima, Jun, Ganz, Tomas, Kowalski, Mark, Brachmann, Carrie Baker

“…Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional…”
Get full text

Zeroing in on cereblon by Heaney, Mark L.

Get full text

Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F by Stein, Brady L, Oh, Stephen T, Berenzon, Dmitriy, Hobbs, Gabriela S, Kremyanskaya, Marina, Rampal, Raajit K, Abboud, Camille N, Adler, Kenneth, Heaney, Mark L, Jabbour, Elias J, Komrokji, Rami S, Moliterno, Alison R, Ritchie, Ellen K, Rice, Lawrence, Mascarenhas, John, Hoffman, Ronald

“…Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a substantial symptom burden, thrombohemorrhagic complications, and…”
Get full text